perioants: Jean

Jean-François MICHELET et al.

Serial No.:

09/917,236

Filing Pate:

July 30, 2001

For: JAN 2 2 2002 R

USE OF NON-PROSTANOIC AGONISTS OF PROSTAGLANDIN EP and a portion of a prostaglandin of a

TRANSMITTAL

Commissioner of Patents Washington, D.C. 20231 Sir:

Transmitted herewith is a **Preliminary Amendment** in the captioned patent application.

___ Small Entity status of this application under 37 C.F.R. 1.9 and 1.27 has been established by a verified statement previously submitted.

A verified Statement to establish small entity status under 37 C.F.R. 1.9 and 1.27 is enclosed.

XX No additional fee is required.

The fee has been calculated as shown below:

Claims Highest				Present	Small Entity		Other Than A Smal	1
Remaining		Number		Extra			Entity	
After		Previously			Rate Addit. (or)		Rate Addit.	
Amendment		Paid For			Fee		<u>Fee</u>	
Total	19	16	- 20 =	0	x 9 = \$	x 18 =	\$	
Indep.	3	3	- 3=0)	x 42 = \$	x 84 =	\$.	

First Presentation of

Multiple Dependent Claims +135 = \$ +270 = \$

Total Additional Fee

Please charge Deposit Account No. 06-1358 in the amount of \$____. A duplicate of this sheet is attached.

If a Petition for Extension of Time is necessary and the Petition and/or the check is not enclosed, this will act as the Petition and applicant herewith petitions the Commissioner to extend the time for response and charge any fees necessary under 37 CFR 1.17 (a)(1)-(5) to Deposit Account No. 06-1358. The Commissioner is also authorized to charge payment of any other additional fees associated with this communication or credit any overpayment to Deposit Account No. 06-1358. A duplicate copy of this sheet is attached.

Date: January 22, 2002 400 Seventh Street, N.W. Washington, D.C. 20004-2201

Attorney Docket No.: 61/P66892US0

HBJ:SKS/vjb

JACOBSON HOLMAN PLLC

Harvey B. Jacobson, Jr

Reg. No. 20,851

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Jean-François MICHELET et al.

Serial No.:

09/917,236

Filing Date:

July 30, 2001

USE OF NON-PROSTANOIC AGONISTS OF PROSPECLANDE EP-2 AND/OR EP-4 RECEPTORS AS COSMETIC ASENTS FOR ATTENUATING, REDUCING OR STOPPING THE LOSSOF

HAIR AND OTHER HAIRS

PRELIMINARY AMENDMENT

missioner of Patents Washington, D.C. 20231

Sir:

Prior to initial examination, please amend the aboveidentified application as follows:

IN THE CLAIMS

Please amend the claims as follows:

- 1. (Amended) A cosmetic composition comprising at least one non-prostanoic agonist of a prostaglandin EP-2 receptor, a nonprostanoic agonist of a prostaglandin EP-4 receptor, or a combination thereof in a cosmetically acceptable medium.
- (Amended) The composition according to Claim 1, wherein the composition comprises from 0.001% to 10% of the agonist by weight relative to the weight of the composition.
- 3. (Twice Amended) The composition according to Claim 1, and further comprising from 0.001% to 10% of a prostaglandin EP-3 receptor antagonist by weight relative to the weight of the